CARLSBAD, Calif.–(BUSINESS WIRE)–Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared new data from the Phase 2 CELIA study showing increasing clinical benefit of diranersen, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in people living with early Alzheimer’s disease at two years (Week 96). Results presented at the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference showed slowing of clinical decline across measures

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.